Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
86 kDa. DTT-reduced protein migrates as 95-110 kDa &125-140 kDa
HEK 293 Cells
Greater than 90% by SDS-PAGE
Measured in a competitive binding assay. When human LDL is immobilized at 1 µg/ml (100 µl/well), recombinant human LDLR inhibits 50% binding of biotinylated recombinant human LDLR (0.5 µg/ml) at the concentration range of 0.35 – 2.5 µg/ml.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from PBS, pH 7.4, mannitol or trehalose
Centrifuge the vial before opening. Reconstitute in sterile PBS, pH 7.4 to 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, store at -20°C.
LDLR Protein, FHC Protein, LDL receptor Protein, LDLCQ2 Protein
The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis.